利格列汀-话题@MedSci

#利格列汀#

9篇内容 | 1129人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2234090, encodeId=ba122234090c0, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a> <a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=BMJ：李延兵团队发现强化-简化降糖方式对初治2型糖尿病患者能实现持久控制血糖, objectType=article, longId=849134, objectId=9541849134bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241023/184ebe96f6f1449caba1ff3276638f6b-2tlUmtqh8hT2.jpg, objectUrl=/article/show_article.do?id=9541849134bd, replyNumber=0, likeNumber=23, createdTime=2024-10-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=9541849134bd, moduleTitle=BMJ：李延兵团队发现强化-简化降糖方式对初治2型糖尿病患者能实现持久控制血糖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9541849134bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1973558, encodeId=6dca19e3558d7, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=Diabetes Obes Metab：二肽基肽酶-4抑制剂利格列汀与磺脲类格列美脲在成人2型糖尿病患者餐后肾血流动力学影响, objectType=article, longId=219911, objectId=452e2199110c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=452e2199110c, replyNumber=0, likeNumber=85, createdTime=2022-02-26, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=452e2199110c, moduleTitle=Diabetes Obes Metab：二肽基肽酶-4抑制剂利格列汀与磺脲类格列美脲在成人2型糖尿病患者餐后肾血流动力学影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=452e2199110c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973557, encodeId=3ab119e3557c3, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=Cardiovasc Diabetol：比较恩格列净+利格列汀与二甲双胍+甘精胰岛素联合降糖方案对肾脏血流动力学影响的差异, objectType=article, longId=219957, objectId=80bd21995e2d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80bd21995e2d, replyNumber=0, likeNumber=79, createdTime=2022-02-01, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80bd21995e2d, moduleTitle=Cardiovasc Diabetol：比较恩格列净+利格列汀与二甲双胍+甘精胰岛素联合降糖方案对肾脏血流动力学影响的差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80bd21995e2d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973556, encodeId=3d3619e3556f2, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=Diabetes Care：利格列汀对伴有心肾合并症2型糖尿病患者认知能力的影响, objectType=article, longId=177440, objectId=d87d1e744043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d87d1e744043, replyNumber=0, likeNumber=122, createdTime=2019-10-02, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d87d1e744043, moduleTitle=Diabetes Care：利格列汀对伴有心肾合并症2型糖尿病患者认知能力的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d87d1e744043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973553, encodeId=38d019e355364, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=Diabetes Obes Metab：恩格列净+利格列汀是2型糖尿病患者的更佳选择？, objectType=article, longId=148197, objectId=8fa614819e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa614819e8c, replyNumber=0, likeNumber=92, createdTime=2018-11-27, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa614819e8c, moduleTitle=Diabetes Obes Metab：恩格列净+利格列汀是2型糖尿病患者的更佳选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa614819e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973555, encodeId=b27e19e355508, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=利格列汀心血管结局试验CAROLINA达到主要终点, objectType=article, longId=160146, objectId=6a171601469f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a171601469f, replyNumber=0, likeNumber=77, createdTime=2019-10-30, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a171601469f, moduleTitle=利格列汀心血管结局试验CAROLINA达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a171601469f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973554, encodeId=ab0f19e35547c, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, objectType=article, longId=156533, objectId=8846156533e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8846156533e5, replyNumber=0, likeNumber=101, createdTime=2019-05-18, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8846156533e5, moduleTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8846156533e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973552, encodeId=3f3019e35527e, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=Cardiovasc Diabetol：2型糖尿病患者ACS或AIS后使用利格列汀安全吗？, objectType=article, longId=129449, objectId=0b3512944904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3512944904, replyNumber=0, likeNumber=84, createdTime=2018-11-14, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3512944904, moduleTitle=Cardiovasc Diabetol：2型糖尿病患者ACS或AIS后使用利格列汀安全吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b3512944904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973551, encodeId=d0d919e355194, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=Diabetes Obes Metab：利格列汀可降低早期2型糖尿病患者的脉搏波速, objectType=article, longId=112096, objectId=fc6111209692, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc6111209692, replyNumber=0, likeNumber=73, createdTime=2018-02-02, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc6111209692, moduleTitle=Diabetes Obes Metab：利格列汀可降低早期2型糖尿病患者的脉搏波速, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc6111209692)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1973550, encodeId=55ba19e355052, content=<a href='/topic/show?id=3ebb3230614' target=_blank style='color:#2F92EE;'>#利格列汀#</a>, objectTitle=BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请, objectType=article, longId=33637, objectId=1d4c3363e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d4c3363e7b, replyNumber=0, likeNumber=87, createdTime=2014-08-28, rootId=0, userName=ms7517674339485982, userId=038e2500100, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d4c3363e7b, moduleTitle=BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d4c3363e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利格列汀

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #二甲双胍# #2型糖尿病# #利格列汀#

BMJ：李延兵团队发现强化-简化降糖方式对初治2型糖尿病患者能实现持久控制血糖

2024-10-30发表于威斯康星

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

Diabetes Obes Metab：二肽基肽酶-4抑制剂利格列汀与磺脲类格列美脲在成人2型糖尿病患者餐后肾血流动力学影响

2022-02-26

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

Cardiovasc Diabetol：比较恩格列净+利格列汀与二甲双胍+甘精胰岛素联合降糖方案对肾脏血流动力学影响的差异

2022-02-01

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

Diabetes Care：利格列汀对伴有心肾合并症2型糖尿病患者认知能力的影响

2019-10-02

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

Diabetes Obes Metab：恩格列净+利格列汀是2型糖尿病患者的更佳选择？

2018-11-27

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

利格列汀心血管结局试验CAROLINA达到主要终点

2019-10-30

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？

2019-05-18

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

Cardiovasc Diabetol：2型糖尿病患者ACS或AIS后使用利格列汀安全吗？

2018-11-14

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

Diabetes Obes Metab：利格列汀可降低早期2型糖尿病患者的脉搏波速

2018-02-02

ms7517674339485982 (审核中...)

前往app查看评论内容

#利格列汀#

BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请

2014-08-28

科室
- - 订阅+
  - 更多科室
工具
服务